- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC
May 29th 2020, 9:26pm
Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.
Zanubrutinib Shows Clinical Activity, Tolerability in Waldenstrom Macroglobulinemia
May 29th 2020, 9:18pm
Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.
Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma
May 29th 2020, 7:22pm
Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.
Tivozanib Showcases Superiority in Relapsed/Refractory RCC
May 29th 2020, 7:16pm
Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.
Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
May 29th 2020, 5:21pm
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC
May 29th 2020, 5:21pm
Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.
Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC
May 29th 2020, 4:30pm
Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).
Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple Myeloma
May 29th 2020, 4:30pm
Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.
Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC
May 29th 2020, 10:01am
Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.
Carfilzomib Triplet Does Not Improve Outcomes Versus Standard of Care in Newly Diagnosed Myeloma
May 29th 2020, 4:15am
The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.
Locoregional Therapy Does Not Improve OS in Advanced Breast Cancer
May 29th 2020, 3:12am
Data from the long-awaited ECOG-ACRIN E2108 trial showed that surgery and radiation to the tumor does not extend overall survival compared with systemic treatment alone in women with stage IV breast cancer.
Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer
May 29th 2020, 1:00am
Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.
Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients
May 29th 2020, 1:00am
The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors
May 29th 2020, 1:00am
Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC
May 29th 2020, 1:00am
Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
May 29th 2020, 1:00am
Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.
Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 29th 2020, 1:00am
Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.
Active Cancer Strongly Associated With Increased COVID-19 Mortality
May 29th 2020, 1:00am
An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.
Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors
May 29th 2020, 1:00am
Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.
Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma
May 29th 2020, 1:00am
Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.